These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

669 related items for PubMed ID: 28847249

  • 1. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
    Farm Hosp; 2017 Sep 01; 41(5):601-610. PubMed ID: 28847249
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
    J Med Econ; 2015 Sep 01; 18(10):763-76. PubMed ID: 25934146
    [Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS.
    Value Health Reg Issues; 2018 Sep 01; 16():74-80. PubMed ID: 30296624
    [Abstract] [Full Text] [Related]

  • 4. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.
    N Engl J Med; 2013 Nov 07; 369(19):1807-18. PubMed ID: 24195548
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
    Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM.
    HIV Med; 2016 Aug 07; 17(7):505-15. PubMed ID: 26663715
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
    Jarrin I, Suarez-Garcia I, Moreno C, Tasias M, Del Romero J, Palacios R, Peraire J, Gorgolas M, Moreno S, Cohort of the Spanish HIV/AIDS Research Network (CoRIS).
    Antivir Ther; 2019 Aug 07; 24(3):167-175. PubMed ID: 30747107
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
    Pialoux G, Marcelin AG, Cawston H, Guilmet C, Finkielsztejn L, Laurisse A, Aubin C.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb 07; 18(1):83-91. PubMed ID: 28741965
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
    McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.
    J Infect Dis; 2013 Feb 15; 207(4):604-11. PubMed ID: 23204164
    [Abstract] [Full Text] [Related]

  • 12. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P, Mills A, Carpio F, Hsu R, DeJesus E, Pierone G, Henegar C, Fusco J, Fusco G, Wohlfeiler M.
    Clin Drug Investig; 2017 Jan 15; 37(1):51-60. PubMed ID: 27587070
    [Abstract] [Full Text] [Related]

  • 13. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F, Bouee S, Jeanbat V, Piontkowsky D, Aragao F, Bosse M.
    J Int AIDS Soc; 2014 Jan 15; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [Abstract] [Full Text] [Related]

  • 14. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, Pearce G.
    Antivir Ther; 2012 Jan 15; 17(6):1011-20. PubMed ID: 22910324
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M.
    Ann Pharmacother; 2020 Jul 15; 54(7):633-643. PubMed ID: 31910643
    [Abstract] [Full Text] [Related]

  • 17. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
    Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA, AIDS Clinical Trials Group Study A5202 Team.
    J Infect Dis; 2011 Oct 15; 204(8):1191-201. PubMed ID: 21917892
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.
    Clin Infect Dis; 2009 Nov 15; 49(10):1591-601. PubMed ID: 19842973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.